OXi 8007

Drug Profile

OXi 8007

Alternative Names: OXi8007

Latest Information Update: 28 Nov 2007

Price : $50

At a glance

  • Originator Baylor University
  • Developer OXiGENE
  • Class Antineoplastics
  • Mechanism of Action Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Eye disorders

Most Recent Events

  • 08 Dec 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 15 Mar 2004 Preclinical trials in Eye disorders in USA (unspecified route)
  • 09 May 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top